129 results on '"Tragni, Gabrina"'
Search Results
2. Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
3. Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
4. Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
5. Supplementary Figure 3 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
6. Supplementary Figure Legend from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
7. Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
8. Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
9. Supplementary Figure 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
10. Supplementary Methods, Figure 1 Legend , Tables 1-2 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma
11. Supplementary Figure 1 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma
12. Data from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma
13. Atypical Spitz tumors in patients younger than 18 years
14. Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
15. Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells
16. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
17. BRAF alterations are associated with complex mutational profiles in malignant melanoma
18. Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine
19. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases
20. Sentinel and Nonsentinel Node Status in Stage IB and II Melanoma Patients: Two-Step Prognostic Indicators of Survival
21. Automated melanoma detection: Multispectral imaging and neural network approach for classification
22. Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
23. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CTL)-defined, Melanocyte-specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-specific CTLs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions
24. The ABCD system of melanoma detection: a spectrophotometric analysis of the asymmetry, border, color, and dimension
25. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
26. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
27. Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study
28. Abstract A89: Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy.
29. Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
30. T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
31. Pure Desmoplastic Melanoma
32. CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma
33. Automated melanoma detection with a novel multispectral imaging system: results of a prospective study
34. Micro-Melanoma Detection. A Clinical Study on 22 Cases of Melanoma with a Diameter Equal to or Less than 3 MM
35. Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial
36. Melanoma Detection
37. Surgical Treatment of Gastric Metastases from Cutaneous Melanoma: Experience of the National Cancer Institute of Milan
38. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma
39. Association between Cutaneous Melanoma and Neurofibromatosis Type 1: Analysis of Three Clinical Cases and Review of the Literature
40. 23 T cell recognition of melanoma antigens and tumour progression
41. Sentinel Node Biopsy and Selective Dissection for Melanoma Nodal Metastases
42. Image Analysis in the RGB and HS Colour Planes for a Computer-Assisted Diagnosis of Cutaneous Pigmented Lesions
43. Melanoma of the External Ear
44. Solitary Melanoma Metastasis of the Kidney: A Case Report
45. In Situ and Very thin Melanomas (< 0.75 mm) are Similarly and Commonly Recognizable
46. Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial
47. Adjuvant multi-peptide vaccination in high risk stage II-III melanoma patients
48. Isolation of cells with cancer initiating capacity in human melanomas
49. Melanotic neuroectodermal tumour of infancy (MNTI)
50. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.